Catheter Precision, Inc. has received approval to commercialize its LockeT product in the United Kingdom.
LockeT is a suture retention device that enhances patient comfort and recovery after cardiac procedures.
The company's partner, HC21, will assist in distributing LockeT in the UK.
LockeT Approval in the UK
LockeT, a suture retention device by Catheter Precision, has obtained approval for commercialization in the UK following its CE Mark approval for European distribution.
Partnership with HC21
Catheter Precision has partnered with HC21, a distributor with a strong presence in the UK and Ireland, to bring LockeT to the market.
Impact on Healthcare Systems
LockeT's approval in the UK is expected to support healthcare systems by enhancing patient care, reducing waiting lists, and accelerating patient throughput.
- LockeT's approval in the UK marks a significant milestone for Catheter Precision, opening up a new market for its innovative medical device.
- The intuitive design and benefits of LockeT not only improve patient outcomes but also align with the NHS's goals of reducing waiting lists and improving treatment efficiency.
Catheter Precision's approval for LockeT in the UK signifies progress in delivering patient-centric solutions and contributing to healthcare system efficiency. The partnership with HC21 and the strategic distribution plans highlight the company's commitment to innovation in cardiac electrophysiology.